Skip to main content
Saline Peptides

Peptide experiments and their comparison groups

Both sides of the experiment

Saline Peptides gives the control group equal billing

The headline percentage comes easily. The comparison group takes more work to remember. Both sides of a peptide experiment deserve my curiosity: the people and animals receiving the compound, and the group supplying its comparison.

Retatrutide and its placebo groupCompare the experiments
A technician calibrating one of two empty weighing stations in a pale measurement room

The placebo group lost weight too

The retatrutide number I’d put back in the headline is 2.1%. That was the mean body-weight reduction in the placebo group at 48 weeks, beside 24.2% in the highest retatrutide arm of the Phase 2 trial involving 338 adults with obesity. Both figures describe people taking part in the same experiment.

The treatment result impresses me. Putting its comparator alongside it makes the result more interesting, because the experiment can begin to separate the effect of the compound from changes that happened without it. It also gives the participants assigned placebo some deserved space. They supplied an essential part of the answer.

Saline is an unshowy name for a site about peptides. It points my curiosity towards that quieter side of an experiment: the vehicle, the placebo, the starting measurement. The studies use different comparison treatments; assuming every placebo contained saline would be a mistake.

Two bars show mean weight reduction of 2.1 percent with placebo and 24.2 percent in the highest retatrutide arm
Mean body-weight reduction at 48 weeks in the Phase 2 obesity trial. The retatrutide bar represents the highest study arm. Jastreboff and colleagues, 2023.

Ipamorelin and MOTS-c comparisons

The same curiosity leads into some less famous experiments. In an ipamorelin bone-growth study in adult female rats, the vehicle group’s bones were already growing at 42 micrometers/day. The treated groups reached 44, 50 and 52 micrometers/day. Total circulating IGF-1 stayed unchanged. That last observation is pleasingly awkward to me: a familiar explanation involving growth hormone and IGF-1 suddenly needs more work.

MOTS-c improved physical performance in mice. Its human record raises a different question. A cohort of people receiving hemodialysis supplied measurements of naturally circulating MOTS-c and subsequent outcomes, rather than a test of giving the peptide to people. An administered compound and a measured biomarker can share a name while answering quite different questions.

Compound pages

Ipamorelin research moves from a precisely timed growth-hormone pulse to the less cooperative results of a bowel-surgery trial. MOTS-c moves between a mouse treadmill, cellular stress and a human blood measurement. Retatrutide clinical trial results provide the largest human experiments here, including their adverse events.

I give a convincing result credit. I reserve a share of the credit for the comparator. The side-by-side study page collects those comparisons; the questions page deals with combinations, preparation and the temptation to turn a study into a personal instruction.